Hassan Elham A, Abdel Rehim Abeer S, Ahmed Asmaa O, Abdullahtif Hanan, Attia Alaa
Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut 71111, Egypt.
Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut 71111, Egypt.
Medicina (Kaunas). 2019 Feb 2;55(2):36. doi: 10.3390/medicina55020036.
Sepsis carries a poor prognosis for critically ill patients, even withintensive management. We aimed to determined early predictors of sepsis-related in-hospital mortality and to monitor levels of presepsin and high sensitivity C reactive protein (hsCRP) during admission relative to the applied treatment and the development of complications.An observational study was conducted on 68 intensive care unit (ICU) patients with sepsis. Blood samples from each patient were collected at admission (day 0) for measuring presepsin, hsCRP, biochemical examination, complete blood picture and microbiological culture and at the third day (day 3) for measuring presepsin and hsCRP. Predictors of sepsis-related in-hospital mortality were assessed using regression analysis. Predictive abilities of presepsin and hsCRP were compared using the area under a receiver operating characteristic curve. The Kaplan⁻Meier method was used to estimate the overall survival rate.Results showed that the sepsis-related in-hospital mortality was 64.6%. The day 0 presepsin and SOFA scores were associated with this mortality. Presepsin levels were significantly higher at days 0 and 3 in non-survivors vs. survivors ( = 0.03 and < 0.001 respectively) and it decreased over the three days in survivors. Presepsin had a higher prognostic accuracy than hsCRP at all the evaluated times. Overall, in comparison with hsCRP, presepsin was an early predictor of sepsis-related in-hospital mortality in ICU patients. Changes in presepsin concentrations over time may be useful for sepsis monitoring, which in turn could be useful for stratifying high-risk patients on ICU admission that benefit from intensive treatment.
脓毒症对重症患者来说预后很差,即便进行强化治疗也是如此。我们旨在确定脓毒症相关院内死亡率的早期预测指标,并在入院期间监测降钙素原和高敏C反应蛋白(hsCRP)水平,同时考虑所应用的治疗方法及并发症的发生情况。
对68例入住重症监护病房(ICU)的脓毒症患者进行了一项观察性研究。在患者入院时(第0天)采集血样,用于检测降钙素原、hsCRP、生化检查、全血细胞计数和微生物培养;在第3天采集血样,用于检测降钙素原和hsCRP。使用回归分析评估脓毒症相关院内死亡率的预测指标。采用受试者工作特征曲线下面积比较降钙素原和hsCRP的预测能力。采用Kaplan-Meier法估计总生存率。
结果显示,脓毒症相关院内死亡率为64.6%。第0天的降钙素原水平和序贯器官衰竭评估(SOFA)评分与该死亡率相关。与存活患者相比,非存活患者在第0天和第3天的降钙素原水平显著更高(分别为P = 0.03和P < 0.001),且存活患者的降钙素原水平在三天内有所下降。在所有评估时间点,降钙素原的预后准确性均高于hsCRP。总体而言,与hsCRP相比,降钙素原是ICU患者脓毒症相关院内死亡率的早期预测指标。降钙素原浓度随时间的变化可能有助于脓毒症的监测,进而有助于在ICU入院时对可从强化治疗中获益的高危患者进行分层。